euroapi.comCrawled Nov 13, 2026
EUROAPI offers nearly 200 active ingredient solutions across multiple therapeutic areas.
Laurent Petit leads EUROAPI’s innovation and external collaboration.
EUROAPI’s research teams developed a method for sustainable solid-phase peptide synthesis using Raman spectroscopy, a rotating bed reactor, and greener solvents.
The EUROAPI Executive Committee comprises 14 members overseeing the Group’s activities.
EUROAPI specializes in active pharmaceutical ingredients, offering around 200 products and developing new molecules through CDMO services.
EUROAPI operates six manufacturing sites across Europe, providing scalable production and innovative technologies.
This form connects users with EUROAPI experts about API solutions or CDMO services.
This page provides the English version of the French general terms and conditions for purchasing.
EuroAPI achieves €848.2 million in net sales for fiscal year 2025. The company’s financial results highlight its performance across its core business segments. This marks a significant milestone in the company’s annual revenue growth trajectory.
Mar 2026EUROAPINews article
EUROAPI sells its Haverhill manufacturing site to Particle Dynamics under its **FOCUS-27** transformation strategy. The deal covers 100% of EUROAPI UK Ltd, which operates the facility. Particle Dynamics specializes in particle processing and finished-dose manufacturing for nutraceutical, consumer health, and pharmaceutical industries.
Jun 2025EUROAPINews article
EuroAPI reports a significant increase in Free Cash Flow before financing for 2024, demonstrating operational resilience amid a difficult economic environment. The company highlights sustained financial performance despite broader market headwinds, though specific figures or strategic shifts are not detailed in the announcement.
Mar 2025EUROAPINews article
EUROAPI appoints Emmanuel Blin as Chair of the Board and David Seignolle as Chief Executive Officer, following the resignations of Viviane Monges and Ludwig de Mot. The company implements leadership changes as it advances its FOCUS-27 strategic plan with secured financing. The Board of Directors approves the transitions through the Nominations and Compensation Committee’s recommendation.
Dec 2024EUROAPINews article